Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $63.0 million.

  • Foghorn Therapeutics' Shares Outstanding (Weighted Average) rose 68.12% to $63.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.0 million, marking a year-over-year increase of 68.12%. This contributed to the annual value of $54.9 million for FY2024, which is 3079.24% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $63.0 million for Q3 2025, which was up 68.12% from $63.0 million recorded in Q2 2025.
  • Foghorn Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $63.0 million during Q3 2025, with a 5-year trough of $36.8 million in Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $46.4 million, with a median of $41.8 million in 2023.
  • As far as peak fluctuations go, Foghorn Therapeutics' Shares Outstanding (Weighted Average) soared by 61431.2% in 2021, and later skyrocketed by 68.12% in 2025.
  • Over the past 5 years, Foghorn Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $37.2 million in 2021, then grew by 11.89% to $41.6 million in 2022, then grew by 0.92% to $42.0 million in 2023, then soared by 30.79% to $54.9 million in 2024, then increased by 14.81% to $63.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $63.0 million for Q3 2025, versus $63.0 million for Q2 2025 and $62.8 million for Q1 2025.